Advertisement

Topics

AstraZeneca PLC Release: Acalabrutinib Granted Breakthrough Therapy Designation By U.S. FDA For The Treatment Of Patients With Mantle Cell Lymphoma

20:00 EDT 31 Jul 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: AstraZeneca PLC Release: Acalabrutinib Granted Breakthrough Therapy Designation By U.S. FDA For The Treatment Of Patients With Mantle Cell Lymphoma

NEXT ARTICLE

More From BioPortfolio on "AstraZeneca PLC Release: Acalabrutinib Granted Breakthrough Therapy Designation By U.S. FDA For The Treatment Of Patients With Mantle Cell Lymphoma"

Quick Search
Advertisement